# EGS Healthcare Capital Partners

> EGS Healthcare Capital Partners is a VC fund backing Medical and Health Care. See 6 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Norwalk, United States
- Total investments: 6
- Last investment: Mar 2006
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.egshealthcare.com

EGS Healthcare Capital Partners is a healthcare private equity firm that invests in late stage private and emerging public healthcare companies with promising commercial products that are either on the market or in late stages of development. The Principals of the firm presently manage two funds with combined committed capital of more than $135million.

## Contacts

5 contacts available for EGS Healthcare Capital Partners. Shizune tracks 1 team members at EGS Healthcare Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/egs-healthcare-capital-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 5 | 83% |
| Health Care | 5 | 83% |
| Medical Device | 3 | 50% |
| Biotechnology | 2 | 33% |
| Genetics | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 50% |
| Series A | 1 | 17% |
| Series C | 1 | 17% |
| Funding Round | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Stefano Ciampolini | Founder | 0 | — |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EKOS Corporation | EKOS Corporation pioneered the development and the clinical application of ultrasound accelerated thrombolysis, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists and vascular surgeons at leading institutions around the world use the EKOS EkoSonic Endovascular System toprovide faster, safer and more complete dissolution of thrombus. | $26M | Series C | Mar 21, 2006 |  |
| Cerexa Inc. | Cerexa is a biopharmaceutical company focused on the development of a portfolio of novel anti-infective therapies for the treatment of serious and life-threatening infections. The company’s product portfolio includes Ceftaroline AcetateCeftaroline, an injectable cephalosporin that is used for the treatment of bacterial infections caused bygram-positive and gram-negative pathogens. | $50M | Series A | Aug 23, 2005 |  |
| Endius | Endius was founded in 1997 to provide less traumatic and more effective surgery for the of patients treated for back pain. The company develops invasive and endoscopic spine surgery products and implants and is committed to developing total spine surgery solutions. The company's products include the Atavi system, the TiTLE, and the MDSmicrodebrider system.Endius is acquired by Zimmer Biomet Holdings. | $15M |  | May 23, 2005 |  |
| Alveolus | Alveolus is a leader in the emerging field of non-vascular interventional stenting through next generation stent technology. | $10M | Series B | Jul 30, 2004 |  |
| Ardais Corporation | Ardais Corporation is a clinical genomics company, is dedicated to enhancing and accelerating biomedical research by introducing actual human disease into the pharmaceutical discovery research process. To achieve its goals, Ardais has incorporated multi-disciplinary scientific expertise into its operations, including pathology, molecular biologyand genomics, statistical genomics, bioinformatics and medical informatics, as well as process management skills such as logistics, industrial engineering, and robotics. The result of this unique integration is a state-of-the-art, proprietary discovery platform that is dramatically transforming genomic research and leading the way to novel diagnostic and therapeutic solutions. | $33.5M | Series B | Mar 20, 2001 |  |
| CytoLogix | CytoLogix is a private company that focuses on developing laboratory instrumentation for non-routine complex stains. The company develops the Artisan, a tissue staining instrument used primarily for cancer diagnosis. It claims that the instrument was the first instrument to provide true walk-away automation for both immunohistochemical and complexspecial stains. | $27.4M | Series B | Jan 29, 2001 |  |

6 of 6 investments shown.

## Co-investors
- [Morgan Stanley Expansion Capital](https://shizune.co/investors/profile/morgan-stanley-expansion-capital) — VC Fund, 2 deals together
- [Advanced Technology Ventures](https://shizune.co/investors/profile/advanced-technology-ventures) — VC Fund, 1 deal together
- [A. M. Pappas & Associates](https://shizune.co/investors/profile/a-m-pappas-associates) — VC Fund, 1 deal together
- [Ascension Ventures](https://shizune.co/investors/profile/ascension-ventures) — VC Fund, 1 deal together
- Boston University — VC Fund, 1 deal together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does EGS Healthcare Capital Partners invest in?

EGS Healthcare Capital Partners invests primarily in Medical, Health Care and Medical Device startups, most often at Series B and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact EGS Healthcare Capital Partners?

Public channels for EGS Healthcare Capital Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at EGS Healthcare Capital Partners?

The team at EGS Healthcare Capital Partners includes Stefano Ciampolini (Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co